Related Experiment Videos
Interpretation of prospective trials in hypertension: do treatment guidelines accurately reflect current evidence?
L E Ramsay1, I ul Haq, W W Yeo
1Department of Medicine and Pharmacology, Royal Hallamshire Hospital, Sheffield, UK.
Insights
Current hypertension guidelines vary significantly, impacting patient treatment numbers and costs. Risk-based guidelines offer improved accuracy but may lack simplicity, necessitating comparative evaluation for optimal hypertension management.
Area of Science:
- Cardiology
- Clinical Pharmacology
- Public Health
Background:
- Prospective controlled trials provide evidence for antihypertensive treatment efficacy and safety.
- Current national and international hypertension management guidelines are reviewed against this evidence.
- Guidelines acknowledge strongest evidence for thiazide diuretics and beta-blockers, particularly for moderate-to-severe hypertension.
Purpose of the Study:
- To assess the satisfactory incorporation of evidence from antihypertensive treatment trials into current guidelines.
- To identify discrepancies and shortcomings in existing hypertension management guidelines.
- To explore the potential of risk-based guidelines as an alternative to conventional approaches.
Main Methods:
- Review of findings from prospective controlled trials on antihypertensive treatment.
- Analysis of current national and international hypertension management guidelines.
- Comparison of conventional and risk-targeted guideline approaches for uncomplicated mild hypertension.
Main Results:
- Conventional guidelines show significant variation in blood pressure thresholds for treatment initiation (e.g., 160/100 mmHg vs. 140/90 mmHg).
- These variations lead to substantial differences in patient populations treated and potential cardiovascular event prevention.
- Risk-based guidelines, targeting absolute cardiovascular disease risk, present a potential improvement but require further evaluation regarding patient acceptability and practical implementation.
Conclusions:
- Conventional guidelines offer simplicity but may lack accuracy in treatment decisions.
- Risk-targeted guidelines offer greater accuracy but may compromise simplicity.
- Comparative evaluation is essential to determine the superior approach for hypertension management outcomes.
Objective:
To review the findings of prospective controlled trials of antihypertensive treatment and determine whether the evidence they have provided is embodied satisfactorily in current national and international guidelines for hypertension management.
Management Guidelines:
Conventional guidelines all advise prompt treatment of moderate-to-severe hypertension and treatment of even mild hypertension in subjects with cardiovascular disease, target organ damage or diabetes, and in the elderly; and treatment of isolated systolic hypertension in the elderly. All acknowledge that evidence for efficacy and safety of treatment is strongest for thiazide diuretics and beta-blockers.
Uncomplicated Mild Hypertension:
Conventional guidelines all emphasize the importance of long-term blood pressure, measured over some months, for treatment decisions. However the blood pressure for routine treatment varies from 160/100 mmHg (British Hypertension Society) to 140/90 mmHg (Joint National Committee V). This dictates very large differences in the number of patients to be treated to prevent a cardiovascular disease event and in the proportion of the population to be treated, yet the reasons for these differences are not explicit. None of the conventional guidelines is entirely satisfactory. The more conservative British Hypertension Society policy may leave untreated some middle-aged men who ought to be treated. The more aggressive Joint National Committee V policy will lead to treatment of some young subjects who have only a remote chance of benefit, at very high cost, and possibly with adverse harm-benefit consequences. RISK-BASED GUIDELINES: Guidelines developed in New Zealand target absolute cardiovascular disease risk in mild hypertension and have the potential to correct this shortcoming of conventional guidelines. However they require further consideration as regards the number needed to treat which is acceptable to well-informed patients, the appropriate estimate of relative cardiovascular disease risk reduction by treatment in mild hypertension, the pattern of treatment which will emerge and their acceptability in ordinary practice.
Conclusion:
Comparative evaluation will be needed to determine whether the outcome is better with conventional guidelines, which are simple but at the expense of accuracy, or with risk-targeted guidelines, which are more accurate but at the expense of simplicity.